Journal article
Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: A phase 3, double-blind, randomised, parallel-group trial
P Kwan, MJ Brodie, R Kälviäinen, L Yurkewicz, J Weaver, LE Knapp
Lancet Neurology | Published : 2011
Abstract
Background: Efficacious and safe monotherapy options are needed for adult patients with newly diagnosed epilepsy. As an adjunctive treatment for partial seizures, pregabalin compares favourably with lamotrigine and is an effective, approved treatment. We studied the efficacy and safety of pregabalin as monotherapy, using a design that complied with European regulatory requirements and International League Against Epilepsy guidelines. Methods: This phase 3, double-blind, randomised, non-inferiority study compared the efficacy and tolerability of pregabalin and lamotrigine monotherapy in patients with newly diagnosed partial seizures at 105 centres, mostly in Europe and Asia. Randomisation to ..
View full abstractGrants
Funding Acknowledgements
[ "Pfizer Inc.", "This Article concerns a use of pregabalin that is not approved by the FDA. PK has served on a speakers' bureau for Eisai, serves on a scientific advisory board for Pfizer Inc, and receives research grants from Eisai, Johnson & Johnson, Pfizer Inc, and UCB Pharma. MJB serves on scientific advisory boards for Pfizer Inc, UCB Pharma, Eisai, Johnson & Johnson, GlaxoSrnithKline, Novartis, Valeant Pharmaceuticals International, Sierra Neuropharmaceuticals, Neuronex, and Medtronic; has received funding for travel from UCB Pharma; serves as a consultant for Sisal; serves on speakers' bureaus for UCB Pharma, GlaxoSmithKline, and Eisai; and has received research support from Pfizer Inc, UCB Pharma, and Eisai. RK has served on scientific advisory boards for Pfizer Inc, UCB Pharma, and GlaxoSmithKline; has received funding for travel from UCB Pharma and Eisai; has served on speakers' bureaus for UCB Pharma, Eisai, and Orion; and has received research support from UCB Pharma. LY, JW, and LK are employees of Pfizer Inc.", "Editorial support was provided by Patricia McChesney of UBC Scientific Solutions and was funded by Pfizer Inc." ]